People · Operator
Named in public records as an officer, director or promoter · active 2009–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Editas Medicine, Inc. | — | Biotechnology | Series D+ | $120.0M | $4.9B | 2015 |
| Dare Bioscience, Inc. | — | Biotechnology | Series B | $102.0M | $93.7M | 2009 |
| Cedilla Therapeutics, Inc. | — | Biotechnology | Series C | $82.6M | $3.1B | 2020 |
| Sensorium Therapeutics, Inc. | — | Pharmaceuticals | Series B | $60.5M | $148.9M | 2025 |
Alexandra Glucksmann at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Alexandra Glucksmann on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Langer | 1 | 36 |
| Kevin Bitterman | 1 | 15 |
| John P Ryan | 1 | 11 |
| Alan Crane | 1 | 9 |
| Terry McGuire | 1 | 8 |
| Kevin Lalande | 1 | 8 |
| Robert Tepper | 1 | 7 |
| Eli Casdin | 1 | 6 |
| Jake Simson | 1 | 6 |
| ABBIE CELNIKER | 1 | 6 |
| Alexis Borisy | 1 | 6 |
| Bryan E. Roberts | 1 | 6 |
| Douglas Cole | 1 | 5 |
| NEIL EXTER | 1 | 5 |
| Andrew Hack | 1 | 5 |
| Katrine Bosley | 1 | 4 |
| Steven E. Hall | 1 | 4 |
| Cheryl R. Blanchard | 1 | 4 |
| Ryan Katz | 1 | 4 |
| David Southwell | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.